#USA #pancreatic cancer #Cary, NC #Drug Delivery #Continuity Biosciences

Continuity Biosciences Begins Pioneering Clinical Trials for Pancreatic Cancer

In a significant stride towards improving pancreatic cancer treatments, Continuity Biosciences, LLC, a clinical-stage biotechnology firm, has announced the launch of its first human clinical trial. This trial aims to assess the efficacy of gemcitabine, a standard chemotherapy drug, delivered via their novel iontophoretic oncology platform (IOP). This platform is uniquely designed to deliver precision drug therapy directly into pancreatic tumors, thus enhancing the drug's effectiveness while minimizing systemic side effects.

The trial, officially listed under ClinicalTrials.gov with the identifier NCT07481383, has commenced patient enrollment at leading academic medical centers, including WVU Medicine J.W. Ruby Memorial Hospital and the Taubman Center at the University of Michigan. These institutions are recognized for their cutting-edge cancer research and treatment facilities.

Continuity Biosciences' innovative IOP technology addresses two of the most pressing challenges in treating pancreatic cancer: drug penetration and systemic toxicity. Current chemotherapy methods often struggle to deliver adequate concentrations of the drug to the tumor site without affecting healthy tissues. The IOP seeks to overcome these hurdles by achieving localized and controlled drug administration directly at the tumor, which could lead to significantly improved therapeutic outcomes.

Ramakrishna "Krishna" Venugopalan, the CEO of Continuity Biosciences, emphasized the trial's importance, stating, "This initial human study marks a crucial milestone in our mission to upend traditional methods of solid tumor therapy administration. By facilitating targeted and localized delivery, we believe our platform can significantly enhance the effectiveness of existing therapies and pave the way for combination treatment strategies across various tumor types."

Pancreatic cancer remains one of the most challenging cancers to treat, typically resulting in low survival rates. Despite recent advancements in systemic therapies, delivering effective concentrations of drugs to pancreatic tumors continues to pose a significant barrier to improving patient outcomes. Dr. Jen Jen Yeh, director of the Pancreatic Cancer Excellence Center at the University of North Carolina's Lineberger Comprehensive Cancer Center, commented on the urgency of developing better treatment options, saying, "Pancreatic cancer is one of the toughest malignancies to manage; patients urgently need improved therapeutic alternatives. Effective and precise delivery of therapies could dramatically enhance patient prognoses."

Dr. Brian Boone, a surgical oncologist at the WVU Cancer Institute and principal investigator of the WVU Medicine study, noted that this trial represents a vital step towards achieving more efficient gemcitabine administration for pancreatic cancer patients. He reiterated the goal of reducing the adverse effects often associated with advanced disease treatments while enhancing clinical outcomes. "Targeting therapy directly to the tumor may significantly improve our ability to manage this disease," he stated.

The challenges of ensuring adequate drug delivery to pancreatic tumors while sparing surrounding healthy tissue have long hindered treatment success. Dr. Benjamin Ferguson, a surgical oncologist at the University of Michigan Medical Center, expressed optimism about the study, suggesting that localized and targeted drug administration might be a breakthrough for gemcitabine and could lead to improved treatment strategies for patients with limited options.

In addition to its focus on pancreatic cancer, Continuity Biosciences is also investigating the broader applicability of its IOP technology in other oncology fields, including localized delivery of carboplatin for head and neck cancers.

Continuity Biosciences is at the forefront of innovative drug delivery solutions aimed at transforming how therapies are administered for various diseases. By targeting the delivery of treatments directly to the affected areas, they seek to maximize therapeutic effectiveness and improve patient care on a global scale. For more information about their groundbreaking approach, visit Continuity Biosciences.